| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.38 | 2e-14 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.28 | 4e-13 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.28 | 9e-12 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | 0.23 | 5e-09 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | 0.23 | 1e-08 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.29 | 2e-07 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.16 | 4e-06 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.16 | 7e-06 |